SANTA CLARITA, CA
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)THE ALFRED E MANN FOUNDATION FOR SCIENTIFIC RESEARCH, founded in 1985, is a mid-sized nonprofit in the Science & Technology sector that reported $18.1M in total revenue in fiscal year 2024. Revenue fell 59% from the prior year — a significant decline worth monitoring. Expenses of $41.8M exceeded revenue, resulting in a 130% operating deficit.
THE ALFRED E. MANN FOUNDATION FOR SCIENTIFIC RESEARCH IS A MEDICAL RESEARCH ORGANIZATION DEDICATED TO DEVELOPING AND COMMERCIALIZING INNOVATIVE SOLUTIONS FOR SIGNIFICANT UNMET MEDICAL CONDITIONS.
NEUROMODULATION SYSTEMADVANCED IMPLANTABLE NEUROMODULATION SYSTEM DEVELOPMENT:THIS PROGRAM COVERS (A) THE MONITORING AND EVALUATION OF SEVERAL EARLY-STAGE ADVANCED RESEARCH AND DEVELOPMENT EFFORTS...
NEUROMODULATION SYSTEMADVANCED IMPLANTABLE NEUROMODULATION SYSTEM DEVELOPMENT:THIS PROGRAM COVERS (A) THE MONITORING AND EVALUATION OF SEVERAL EARLY-STAGE ADVANCED RESEARCH AND DEVELOPMENT EFFORTS UNDERWAY THAT ARE DIRECTED AT DEVELOPING INNOVATIVE TECHNOLOGIES, PROJECT IDEAS AND CONCEPTS BEFORE THEY PROGRESS TO THE STATUS OF FULL-FLEDGED DEVELOPMENT PROGRAMS, AND (B) ONGOING EFFORTS RELATED TO THE ADVANCEMENT OF COMMERCIAL READINESS AND PROTECTION OF RELATED INTELLECTUAL PROPERTY ACROSS THE DEVELOPMENT LIFECYCLE. THE TEAM COMPRISES THE FULL RANGE OF EXPERTISE AVAILABLE AT AMF, INCLUDING EXECUTIVE MANAGEMENT, RESEARCH SCIENTISTS AND ENGINEERS, LEGAL AND INTELLECTUAL PROPERTY EXPERTS, BUSINESS DEVELOPMENT STRATEGISTS AND ANALYSTS.STATUS RESEARCH AND DEVELOPMENT ACTIVITIES ARE UNDERWAY TO ENHANCE THE CAPABILITIES OF A NEUROMODULATION SYSTEM, COMPRISED OF ADVANCED TECHNOLOGIES AND SYSTEM SOLUTIONS IN SUPPORT OF NEW BUSINESS DEVELOPMENT STRATEGIES.
NEW PROJECT DEVELOPMENTTHIS PROGRAM COVERS (A) THE MONITORING AND EVALUATION OF SEVERAL EARLY STAGE ADVANCED RESEARCH AND DEVELOPMENT EFFORTS UNDERWAY THAT ARE DIRECTED AT DEVELOPING - INNOVATIVE...
NEW PROJECT DEVELOPMENTTHIS PROGRAM COVERS (A) THE MONITORING AND EVALUATION OF SEVERAL EARLY STAGE ADVANCED RESEARCH AND DEVELOPMENT EFFORTS UNDERWAY THAT ARE DIRECTED AT DEVELOPING - INNOVATIVE TECHNOLOGIES, PROJECT IDEAS AND CONCEPTS BEFORE THEY PROGRESS TO THE STATUS OF FULL-FLEDGED DEVELOPMENT PROGRAMS, AND (B) ONGOING EFFORTS RELATED TO THE ADVANCEMENT OF COMMERCIAL DEVELOPMENT AND PROTECTION OF INTELLECTUAL PROPERTY OF THESE PROJECTS ACROSS THE DEVELOPMENT LIFECYCLE. THE TEAM COMPRISES THE FULL RANGE OF EXPERTISE AVAILABLE AT AMF, INCLUDING - EXECUTIVE MANAGEMENT, RESEARCH SCIENTISTS AND ENGINEERS, LEGAL AND INTELLECTUAL PROPERTY EXPERTS, BUSINESS DEVELOPMENT STRATEGISTS AND ANALYSTS.EXPENSES MAY INCLUDE ONGOING PARTICIPATION IN THE DEVELOPMENT EFFORT INCLUDING RESEARCH AND DEVELOPMENT SUPPORT, COLLABORATION MANAGEMENT, CONFERENCE AND PROFESSIONAL SOCIETY MEETING ATTENDANCE, SERVICE IN MANAGEMENT OR ON THE BOARD OF DIRECTORS OF SPINOUT ENTITIES, PATENT PROSECUTION AND THE PROSECUTION OF INFRINGEMENT ACTIONS TO PROTECT THE VALUE OF THE INTELLECTUAL PROPERTY WE CREATE. IN ADDITION TO PAYROLL EXPENSES AND DIRECT EXPENSES PAID TO OUTSIDE VENDORS FOR GOODS AND SERVICES RELATED TO PROJECTS, EXPENSES IN THIS PROGRAM MAY INCLUDE TRAVEL EXPENSES, PATENT PROSECUTION EXPENSES AND FEES, LEGAL FEES (FOR INTERNAL AND OUTSIDE LEGAL COUNSEL) FOR EXPENSES TO CREATE, PRESERVE AND PROTECT INTELLECTUAL PROPERTY FROM INFRINGEMENT AND REMEDY PAST INFRINGEMENT, AND INCENTIVE AND OTHER COMPENSATION PAYMENTS TO EMPLOYEES AND OTHERS RELATED TO THESE PROGRAMS AND ACTIONS. IN SOME CASES, CERTAIN OF THESE EXPENDITURES MIGHT BE INCURRED LONG AFTER THE PROJECTS HAVE BEEN LAUNCHED INTO SPINOUT COMPANIES OR LICENSED TO THIRD PARTIES.REVENUES ASSOCIATED WITH THESE PROJECTS (SOME OF WHICH MAY ACCRUE LONG AFTER THE PROJECT AND ANY RELATED PROGRAM HAVE BEEN OUT-LICENSED OR LAUNCHED INTO A SPINOUT COMPANY) MAY INCLUDE RECOVERIES OF JUDGMENTS OR SETTLEMENTS FROM PATENT INFRINGEMENT MATTERS, ROYALTIES ON NET SALES OF LICENSED PRODUCTS, MILESTONE PAYMENTS, ONGOING CONTRACT R&D FROM PARTNERS, LICENSEES AND SPINOUT COMPANIES, INTEREST, AND PROCEEDS OF LIQUIDITY EVENTS (E.G., INITIAL PUBLIC OFFERINGS, ACQUISITIONS) INVOLVING RETAINED EQUITY INTERESTS IN PROJECTS THAT HAVE BEEN SPUN OUT AS STARTUP COMPANIES.STATUS:DESIGN AND DEVELOPMENT ACTIVITIES ARE UNDERWAY FOR A NEW BIOELECTRONIC PROGRAM BASED ON THE BUSINESS CASE ANALYSIS CONDUCTED IN THE PRIOR YEAR. THESE ACTIVITIES INCLUDED GENERATION OF INITIAL SYSTEM REQUIREMENTS, ASSEMBLY OF A TEAM OF KEY OPINION LEADERS WITH DOMAIN EXPERTISE, AND THE INITIATION OF SOME FUNDAMENTAL APPLIED RESEARCH IN THE AREA OF NOVEL ELECTRODE DESIGN, INCLUDING COMPLETION OF PRE-CLINICAL TESTING. ADDITIONALLY, THE BUSINESS DEVELOPMENT TEAM, ALONG WITH EXECUTIVE MANAGEMENT AND OTHER STAFF, PERFORMED PRELIMINARY DUE DILIGENCE ON A NUMBER OF ASSETS.
IMPLANTABLE NEUROMODULATION PROJECT #1 TO TREAT CHRONIC DISEASE THE AIM OF THE AMF PROGRAM IS TO DEVELOP A NEUROSTIMULATION SYSTEM THAT WILL IMPROVE MEDICAL OUTCOMES AT A LOWER COST AND/OR HIGHER...
IMPLANTABLE NEUROMODULATION PROJECT #1 TO TREAT CHRONIC DISEASE THE AIM OF THE AMF PROGRAM IS TO DEVELOP A NEUROSTIMULATION SYSTEM THAT WILL IMPROVE MEDICAL OUTCOMES AT A LOWER COST AND/OR HIGHER PATIENT SATISFACTION THAN CURRENTLY AVAILABLE TREATMENT OPTIONS. SUCH A SYSTEM WILL CONSIST OF A FULLY IMPLANTABLE NEURAL STIMULATOR FOR SEAMLESS OPERATION AND REQUIRING MINIMAL INTERACTION FROM A PATIENT, WITH THE GOAL OF OFFERING A HIGHER LEVEL OF PATIENT SATISFACTION, ADOPTION, AND COMPLIANCE.STATUS:FINAL DESIGN VERIFICATION TESTING ACTIVITIES OF THE IMPLANTABLE DEVICE AND EXTERNALS ARE UNDERWAY IN SUPPORT OF A FIRST-IN-HUMAN STUDY. DESIGN AND MANUFACTURING IMPROVEMENTS HAVE BEEN MADE; PRE-CLINICAL ANIMAL STUDIES WERE COMPLETED.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2024 | 2023 | Change | |
|---|---|---|---|
| Revenue | $18,144,382 | $44,147,259 | -0.6% |
| Expenses | $41,776,524 | $31,844,936 | +0.3% |
| Net Income | $-23,632,142 | $12,302,323 | -2.9% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| ROBERT GREENBERG | CEO/PRESIDENT/CHAIR OF THE BOARD | 44.00 |
Officer
Director
|
$1,176,449 | $145,692 | $1,322,141 |
| KEN WEATHERWAX | BOARD MEMBER | 1.25 |
Director
|
$0 | $0 | $0 |
| RICHARD WAUGH | BOARD MEMBER | 1.50 |
Director
|
$0 | $0 | $0 |
| DAVID GILL | BOARD MEMBER | 1.50 |
Director
|
$0 | $0 | $0 |
| HEATHER PAGE | BOARD MEMBER | 1.25 |
Director
|
$0 | $0 | $0 |
| FARAH BOROOMAND | CHIEF FINANCIAL OFFICER/TREASURER | 44.00 |
Officer
|
$510,007 | $64,791 | $574,798 |
| COREY DISHMON | CHIEF BUSINESS AND LEGAL OFFICER | 40.00 |
Officer
|
$404,186 | $23,740 | $427,926 |
| PHILIP LEE | SECRETARY/ASSISTANT GENERAL COUNSEL | 40.00 |
Officer
|
$216,632 | $39,503 | $256,135 |
| JOHN RIVERA | VICE PRESIDENT, PRODUCT DEVELOPMENT | 41.00 |
Key Emp
|
$357,505 | $32,174 | $389,679 |
| CEDRIC NAVARRO | V.P. QUALITY ASSURANCE, REG. AFFAIRS, INTERIM | 40.00 |
Key Emp
|
$283,665 | $53,331 | $336,996 |
| NEIL TALBOT | VP, RESEARCH AND TECHNOLOGY | 42.00 |
Highest
|
$321,393 | $39,729 | $361,122 |
| SHAWN LEWIS | VICE PRESIDENT, HUMAN RESOURCES | 40.00 |
Highest
|
$318,397 | $39,172 | $357,569 |
| BRIAN MECH | VP, STRATEGY | 40.00 |
Highest
|
$306,807 | $9,977 | $316,784 |
| VALMA KLEIN | VP, CLINICAL AFFAIRS | 41.00 |
Highest
|
$274,441 | $32,066 | $306,507 |
| CARL BUICE | SENIOR DIRECTOR, PROJECT MANAGEMENT | 40.00 |
Highest
|
$280,991 | $43,754 | $324,745 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2025 | $18,144,382 | $41,776,524 | $353,361,768 | $-23,632,142 |
| 2024 | $44,147,259 | $31,844,936 | $372,537,856 | $12,302,323 |
| 2023 | $31,054,042 | $22,822,234 | $344,680,217 | $8,231,808 |
| 2022 | $128,538,828 | $18,142,697 | $374,343,975 | $110,396,131 |
| 2021 | $225,963,433 | $22,418,205 | $307,411,437 | $203,545,228 |
| 2020 | $2,312,474 | $13,859,108 | $59,071,014 | $-11,546,634 |
Compare THE ALFRED E MANN FOUNDATION FOR SCIENTIFIC RESEARCH with other nonprofits in California and across the country.